The Impact of Breast Cancer Treatment Delays on Survival Among South African Women
In high-income settings, delays from breast cancer (BC) diagnosis to initial treatment worsen overall survival (OS). We examined how time to BC treatment initiation (TTI) impacts OS in South Africa (SA). We evaluated women enrolled in the South African BC and HIV Outcomes study between July 1, 2015...
Gespeichert in:
Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2022-03, Vol.27 (3), p.e233-e243 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e243 |
---|---|
container_issue | 3 |
container_start_page | e233 |
container_title | The oncologist (Dayton, Ohio) |
container_volume | 27 |
creator | Pumpalova, Yoanna S Ayeni, Oluwatosin A Chen, Wenlong Carl Buccimazza, Ines Cačala, Sharon Stopforth, Laura W Farrow, Hayley A Mapanga, Witness Nietz, Sarah Phakathi, Boitumelo Joffe, Maureen McCormack, Valerie Jacobson, Judith S Crew, Katherine D Neugut, Alfred I Ruff, Paul Cubasch, Herbert O'Neil, Daniel S |
description | In high-income settings, delays from breast cancer (BC) diagnosis to initial treatment worsen overall survival (OS). We examined how time to BC treatment initiation (TTI) impacts OS in South Africa (SA).
We evaluated women enrolled in the South African BC and HIV Outcomes study between July 1, 2015 and June 30, 2019, selecting women with stages I-III BC who received surgery and chemotherapy. We constructed a linear regression model estimating the impact of sociodemographic and clinical factors on TTI and separate multivariable Cox proportional hazard models by first treatment (surgery and neoadjuvant chemotherapy (NAC)) assessing the effect of TTI (in 30-day increments) on OS.
Of 1260 women, 45.6% had upfront surgery, 54.4% had NAC, and 19.5% initiated treatment >90 days after BC diagnosis. Compared to the surgery group, more women in the NAC group had stage III BC (34.8% vs 81.5%). Living further away from a hospital and having hormone receptor positive (vs negative) BC was associated with longer TTI (8 additional days per 100 km, P = .003 and 8 additional days, P = .01, respectively), while Ki67 proliferation index >20 and upfront surgery (vs NAC) was associated with shorter TTI (12 and 9 days earlier; P = .0001 and.007, respectively). Treatment initiation also differed among treating hospitals (P < .0001). Additional 30-day treatment delays were associated with worse survival in the surgery group (HR 1.11 [95%CI 1.003-1.22]), but not in the NAC group.
Delays in BC treatment initiation are common in SA public hospitals and are associated with worse survival among women treated with upfront surgery. |
doi_str_mv | 10.1093/oncolo/oyab054 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8914482</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A780130832</galeid><sourcerecordid>A780130832</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-d6659f62b11e2ccb3d224a2daab4e46b42f3d808da5c71fd29f3125cc297aefc3</originalsourceid><addsrcrecordid>eNptkctrGzEQxkVpaB7ttcci6KWXTfTahy4F10nbQCCQuCQ3MauVbJVdyZF2Df7vI2M3NBB00MzoNx8z-hD6TMk5JZJfBK9DHy7CFlpSinfohJZCFkKSx_c5Jg0valrKY3Sa0l9CcsjZB3TMS1aLmjQn6G6xMvh6WIMecbD4RzSQRjwHr03Ei5yNg_EjvjQ9bBMOHt9PceM20OPZEPwS34dpXOGZjU6Dxw8h0x_RkYU-mU-H-wz9-Xm1mP8ubm5_Xc9nN4UWZT0WXVWV0laspdQwrVveMSaAdQCtMKJqBbO8a0jTQalrajsmLaes1JrJGozV_Ax93-uup3Ywnc5zRujVOroB4lYFcOr1i3crtQwb1UgqRMOywLeDQAxPk0mjGlzSpu_BmzAlxSre1LSSvMro1z26hN4o523IinqHq1ndEMrzT-8Ez9-g8unM4HTwxrpcf6tBx5BSNPZlekrUzl-191cd_M0NX_7f-QX_Zyh_Bql_o9E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638716936</pqid></control><display><type>article</type><title>The Impact of Breast Cancer Treatment Delays on Survival Among South African Women</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Pumpalova, Yoanna S ; Ayeni, Oluwatosin A ; Chen, Wenlong Carl ; Buccimazza, Ines ; Cačala, Sharon ; Stopforth, Laura W ; Farrow, Hayley A ; Mapanga, Witness ; Nietz, Sarah ; Phakathi, Boitumelo ; Joffe, Maureen ; McCormack, Valerie ; Jacobson, Judith S ; Crew, Katherine D ; Neugut, Alfred I ; Ruff, Paul ; Cubasch, Herbert ; O'Neil, Daniel S</creator><creatorcontrib>Pumpalova, Yoanna S ; Ayeni, Oluwatosin A ; Chen, Wenlong Carl ; Buccimazza, Ines ; Cačala, Sharon ; Stopforth, Laura W ; Farrow, Hayley A ; Mapanga, Witness ; Nietz, Sarah ; Phakathi, Boitumelo ; Joffe, Maureen ; McCormack, Valerie ; Jacobson, Judith S ; Crew, Katherine D ; Neugut, Alfred I ; Ruff, Paul ; Cubasch, Herbert ; O'Neil, Daniel S</creatorcontrib><description>In high-income settings, delays from breast cancer (BC) diagnosis to initial treatment worsen overall survival (OS). We examined how time to BC treatment initiation (TTI) impacts OS in South Africa (SA).
We evaluated women enrolled in the South African BC and HIV Outcomes study between July 1, 2015 and June 30, 2019, selecting women with stages I-III BC who received surgery and chemotherapy. We constructed a linear regression model estimating the impact of sociodemographic and clinical factors on TTI and separate multivariable Cox proportional hazard models by first treatment (surgery and neoadjuvant chemotherapy (NAC)) assessing the effect of TTI (in 30-day increments) on OS.
Of 1260 women, 45.6% had upfront surgery, 54.4% had NAC, and 19.5% initiated treatment >90 days after BC diagnosis. Compared to the surgery group, more women in the NAC group had stage III BC (34.8% vs 81.5%). Living further away from a hospital and having hormone receptor positive (vs negative) BC was associated with longer TTI (8 additional days per 100 km, P = .003 and 8 additional days, P = .01, respectively), while Ki67 proliferation index >20 and upfront surgery (vs NAC) was associated with shorter TTI (12 and 9 days earlier; P = .0001 and.007, respectively). Treatment initiation also differed among treating hospitals (P < .0001). Additional 30-day treatment delays were associated with worse survival in the surgery group (HR 1.11 [95%CI 1.003-1.22]), but not in the NAC group.
Delays in BC treatment initiation are common in SA public hospitals and are associated with worse survival among women treated with upfront surgery.</description><identifier>ISSN: 1083-7159</identifier><identifier>ISSN: 1549-490X</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1093/oncolo/oyab054</identifier><identifier>PMID: 35274708</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - surgery ; Cancer ; Care and treatment ; Chemotherapy ; Chemotherapy, Adjuvant ; Diagnosis ; Event history analysis ; Female ; Global Health and Cancer ; Health aspects ; Humans ; Male ; Methods ; Neoadjuvant Therapy ; Patient outcomes ; Proportional Hazards Models ; South Africa - epidemiology ; Women</subject><ispartof>The oncologist (Dayton, Ohio), 2022-03, Vol.27 (3), p.e233-e243</ispartof><rights>The Author(s) 2022. Published by Oxford University Press.</rights><rights>COPYRIGHT 2022 Oxford University Press</rights><rights>The Author(s) 2022. Published by Oxford University Press. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-d6659f62b11e2ccb3d224a2daab4e46b42f3d808da5c71fd29f3125cc297aefc3</citedby><cites>FETCH-LOGICAL-c457t-d6659f62b11e2ccb3d224a2daab4e46b42f3d808da5c71fd29f3125cc297aefc3</cites><orcidid>0000-0002-9637-2962 ; 0000-0001-5520-9264</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914482/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914482/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27915,27916,53782,53784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35274708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pumpalova, Yoanna S</creatorcontrib><creatorcontrib>Ayeni, Oluwatosin A</creatorcontrib><creatorcontrib>Chen, Wenlong Carl</creatorcontrib><creatorcontrib>Buccimazza, Ines</creatorcontrib><creatorcontrib>Cačala, Sharon</creatorcontrib><creatorcontrib>Stopforth, Laura W</creatorcontrib><creatorcontrib>Farrow, Hayley A</creatorcontrib><creatorcontrib>Mapanga, Witness</creatorcontrib><creatorcontrib>Nietz, Sarah</creatorcontrib><creatorcontrib>Phakathi, Boitumelo</creatorcontrib><creatorcontrib>Joffe, Maureen</creatorcontrib><creatorcontrib>McCormack, Valerie</creatorcontrib><creatorcontrib>Jacobson, Judith S</creatorcontrib><creatorcontrib>Crew, Katherine D</creatorcontrib><creatorcontrib>Neugut, Alfred I</creatorcontrib><creatorcontrib>Ruff, Paul</creatorcontrib><creatorcontrib>Cubasch, Herbert</creatorcontrib><creatorcontrib>O'Neil, Daniel S</creatorcontrib><title>The Impact of Breast Cancer Treatment Delays on Survival Among South African Women</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>In high-income settings, delays from breast cancer (BC) diagnosis to initial treatment worsen overall survival (OS). We examined how time to BC treatment initiation (TTI) impacts OS in South Africa (SA).
We evaluated women enrolled in the South African BC and HIV Outcomes study between July 1, 2015 and June 30, 2019, selecting women with stages I-III BC who received surgery and chemotherapy. We constructed a linear regression model estimating the impact of sociodemographic and clinical factors on TTI and separate multivariable Cox proportional hazard models by first treatment (surgery and neoadjuvant chemotherapy (NAC)) assessing the effect of TTI (in 30-day increments) on OS.
Of 1260 women, 45.6% had upfront surgery, 54.4% had NAC, and 19.5% initiated treatment >90 days after BC diagnosis. Compared to the surgery group, more women in the NAC group had stage III BC (34.8% vs 81.5%). Living further away from a hospital and having hormone receptor positive (vs negative) BC was associated with longer TTI (8 additional days per 100 km, P = .003 and 8 additional days, P = .01, respectively), while Ki67 proliferation index >20 and upfront surgery (vs NAC) was associated with shorter TTI (12 and 9 days earlier; P = .0001 and.007, respectively). Treatment initiation also differed among treating hospitals (P < .0001). Additional 30-day treatment delays were associated with worse survival in the surgery group (HR 1.11 [95%CI 1.003-1.22]), but not in the NAC group.
Delays in BC treatment initiation are common in SA public hospitals and are associated with worse survival among women treated with upfront surgery.</description><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - surgery</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Diagnosis</subject><subject>Event history analysis</subject><subject>Female</subject><subject>Global Health and Cancer</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Male</subject><subject>Methods</subject><subject>Neoadjuvant Therapy</subject><subject>Patient outcomes</subject><subject>Proportional Hazards Models</subject><subject>South Africa - epidemiology</subject><subject>Women</subject><issn>1083-7159</issn><issn>1549-490X</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkctrGzEQxkVpaB7ttcci6KWXTfTahy4F10nbQCCQuCQ3MauVbJVdyZF2Df7vI2M3NBB00MzoNx8z-hD6TMk5JZJfBK9DHy7CFlpSinfohJZCFkKSx_c5Jg0valrKY3Sa0l9CcsjZB3TMS1aLmjQn6G6xMvh6WIMecbD4RzSQRjwHr03Ei5yNg_EjvjQ9bBMOHt9PceM20OPZEPwS34dpXOGZjU6Dxw8h0x_RkYU-mU-H-wz9-Xm1mP8ubm5_Xc9nN4UWZT0WXVWV0laspdQwrVveMSaAdQCtMKJqBbO8a0jTQalrajsmLaes1JrJGozV_Ax93-uup3Ywnc5zRujVOroB4lYFcOr1i3crtQwb1UgqRMOywLeDQAxPk0mjGlzSpu_BmzAlxSre1LSSvMro1z26hN4o523IinqHq1ndEMrzT-8Ez9-g8unM4HTwxrpcf6tBx5BSNPZlekrUzl-191cd_M0NX_7f-QX_Zyh_Bql_o9E</recordid><startdate>20220311</startdate><enddate>20220311</enddate><creator>Pumpalova, Yoanna S</creator><creator>Ayeni, Oluwatosin A</creator><creator>Chen, Wenlong Carl</creator><creator>Buccimazza, Ines</creator><creator>Cačala, Sharon</creator><creator>Stopforth, Laura W</creator><creator>Farrow, Hayley A</creator><creator>Mapanga, Witness</creator><creator>Nietz, Sarah</creator><creator>Phakathi, Boitumelo</creator><creator>Joffe, Maureen</creator><creator>McCormack, Valerie</creator><creator>Jacobson, Judith S</creator><creator>Crew, Katherine D</creator><creator>Neugut, Alfred I</creator><creator>Ruff, Paul</creator><creator>Cubasch, Herbert</creator><creator>O'Neil, Daniel S</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9637-2962</orcidid><orcidid>https://orcid.org/0000-0001-5520-9264</orcidid></search><sort><creationdate>20220311</creationdate><title>The Impact of Breast Cancer Treatment Delays on Survival Among South African Women</title><author>Pumpalova, Yoanna S ; Ayeni, Oluwatosin A ; Chen, Wenlong Carl ; Buccimazza, Ines ; Cačala, Sharon ; Stopforth, Laura W ; Farrow, Hayley A ; Mapanga, Witness ; Nietz, Sarah ; Phakathi, Boitumelo ; Joffe, Maureen ; McCormack, Valerie ; Jacobson, Judith S ; Crew, Katherine D ; Neugut, Alfred I ; Ruff, Paul ; Cubasch, Herbert ; O'Neil, Daniel S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-d6659f62b11e2ccb3d224a2daab4e46b42f3d808da5c71fd29f3125cc297aefc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - surgery</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Diagnosis</topic><topic>Event history analysis</topic><topic>Female</topic><topic>Global Health and Cancer</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Male</topic><topic>Methods</topic><topic>Neoadjuvant Therapy</topic><topic>Patient outcomes</topic><topic>Proportional Hazards Models</topic><topic>South Africa - epidemiology</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pumpalova, Yoanna S</creatorcontrib><creatorcontrib>Ayeni, Oluwatosin A</creatorcontrib><creatorcontrib>Chen, Wenlong Carl</creatorcontrib><creatorcontrib>Buccimazza, Ines</creatorcontrib><creatorcontrib>Cačala, Sharon</creatorcontrib><creatorcontrib>Stopforth, Laura W</creatorcontrib><creatorcontrib>Farrow, Hayley A</creatorcontrib><creatorcontrib>Mapanga, Witness</creatorcontrib><creatorcontrib>Nietz, Sarah</creatorcontrib><creatorcontrib>Phakathi, Boitumelo</creatorcontrib><creatorcontrib>Joffe, Maureen</creatorcontrib><creatorcontrib>McCormack, Valerie</creatorcontrib><creatorcontrib>Jacobson, Judith S</creatorcontrib><creatorcontrib>Crew, Katherine D</creatorcontrib><creatorcontrib>Neugut, Alfred I</creatorcontrib><creatorcontrib>Ruff, Paul</creatorcontrib><creatorcontrib>Cubasch, Herbert</creatorcontrib><creatorcontrib>O'Neil, Daniel S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pumpalova, Yoanna S</au><au>Ayeni, Oluwatosin A</au><au>Chen, Wenlong Carl</au><au>Buccimazza, Ines</au><au>Cačala, Sharon</au><au>Stopforth, Laura W</au><au>Farrow, Hayley A</au><au>Mapanga, Witness</au><au>Nietz, Sarah</au><au>Phakathi, Boitumelo</au><au>Joffe, Maureen</au><au>McCormack, Valerie</au><au>Jacobson, Judith S</au><au>Crew, Katherine D</au><au>Neugut, Alfred I</au><au>Ruff, Paul</au><au>Cubasch, Herbert</au><au>O'Neil, Daniel S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Breast Cancer Treatment Delays on Survival Among South African Women</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2022-03-11</date><risdate>2022</risdate><volume>27</volume><issue>3</issue><spage>e233</spage><epage>e243</epage><pages>e233-e243</pages><issn>1083-7159</issn><issn>1549-490X</issn><eissn>1549-490X</eissn><abstract>In high-income settings, delays from breast cancer (BC) diagnosis to initial treatment worsen overall survival (OS). We examined how time to BC treatment initiation (TTI) impacts OS in South Africa (SA).
We evaluated women enrolled in the South African BC and HIV Outcomes study between July 1, 2015 and June 30, 2019, selecting women with stages I-III BC who received surgery and chemotherapy. We constructed a linear regression model estimating the impact of sociodemographic and clinical factors on TTI and separate multivariable Cox proportional hazard models by first treatment (surgery and neoadjuvant chemotherapy (NAC)) assessing the effect of TTI (in 30-day increments) on OS.
Of 1260 women, 45.6% had upfront surgery, 54.4% had NAC, and 19.5% initiated treatment >90 days after BC diagnosis. Compared to the surgery group, more women in the NAC group had stage III BC (34.8% vs 81.5%). Living further away from a hospital and having hormone receptor positive (vs negative) BC was associated with longer TTI (8 additional days per 100 km, P = .003 and 8 additional days, P = .01, respectively), while Ki67 proliferation index >20 and upfront surgery (vs NAC) was associated with shorter TTI (12 and 9 days earlier; P = .0001 and.007, respectively). Treatment initiation also differed among treating hospitals (P < .0001). Additional 30-day treatment delays were associated with worse survival in the surgery group (HR 1.11 [95%CI 1.003-1.22]), but not in the NAC group.
Delays in BC treatment initiation are common in SA public hospitals and are associated with worse survival among women treated with upfront surgery.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>35274708</pmid><doi>10.1093/oncolo/oyab054</doi><orcidid>https://orcid.org/0000-0002-9637-2962</orcidid><orcidid>https://orcid.org/0000-0001-5520-9264</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1083-7159 |
ispartof | The oncologist (Dayton, Ohio), 2022-03, Vol.27 (3), p.e233-e243 |
issn | 1083-7159 1549-490X 1549-490X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8914482 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - surgery Cancer Care and treatment Chemotherapy Chemotherapy, Adjuvant Diagnosis Event history analysis Female Global Health and Cancer Health aspects Humans Male Methods Neoadjuvant Therapy Patient outcomes Proportional Hazards Models South Africa - epidemiology Women |
title | The Impact of Breast Cancer Treatment Delays on Survival Among South African Women |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T01%3A19%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Breast%20Cancer%20Treatment%20Delays%20on%20Survival%20Among%20South%20African%20Women&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Pumpalova,%20Yoanna%20S&rft.date=2022-03-11&rft.volume=27&rft.issue=3&rft.spage=e233&rft.epage=e243&rft.pages=e233-e243&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1093/oncolo/oyab054&rft_dat=%3Cgale_pubme%3EA780130832%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638716936&rft_id=info:pmid/35274708&rft_galeid=A780130832&rfr_iscdi=true |